Long-form writing on EVs, grounded in the data.
Articles on extracellular vesicle science, characterization standards, and the questions clinicians and partners actually ask. No press-release cadence. No marketing-grade hedging. The published evidence, read carefully, with the limits stated where they sit.
12 pieces, authored by the founding team.
Communicating EV science to patients: a plain-language guide for clinicians
Patients now arrive asking about exosome skincare. The science is real, the evidence is early, and the marketing runs ahead of both. Here is how to explain what an extracellular vesicle product can and cannot do, in words a patient can follow.
Frédéric St-Denis-Bissonnette, PhD
How to choose a plant-derived exosome (EV) supplier: the questions buyers should ask
More clinics and brands now ask for plant-derived rather than human-derived extracellular vesicles. The category is young, the labels are loose, and two products from the same plant can be very different. Ten questions separate a characterized supplier from a label.
Frédéric St-Denis-Bissonnette, PhD
Topical, microneedling or injectable: what sterility and endotoxin testing tell you about an EV (exosome) product
The same vial of extracellular vesicles can be a reasonable cosmetic and an unsafe injectable. What separates them is not the vesicles. It is sterility, endotoxin, and the regulatory class the product was made for.
Frédéric St-Denis-Bissonnette, PhD
Freeze-dried extracellular vesicles (exosomes): does lyophilization damage them, and how should they be stored?
Extracellular vesicles can still be present in a vial long after they have stopped doing anything. Storage, not isolation, is where many EV products quietly lose their activity. Freeze-drying can fix that, if it is done and checked properly.
Frédéric St-Denis-Bissonnette, PhD
What extracellular vesicles actually are, and why "exosome" is the wrong word for most products
EVs are not a category of skincare ingredient. They are a class of biological particles defined by how they are made. Three biogenesis routes, three subpopulations, and a vocabulary problem that has shaped the entire commercial market.
Frédéric St-Denis-Bissonnette, PhD
Plant-derived versus mammalian extracellular vesicles, compared honestly
Both are bilayer-enclosed nanoscale particles. The differences in safety, scalability, regulatory pathway, and clinical evidence are not minor. They are the reason the two modalities belong in different parts of the EV product map.
Frédéric St-Denis-Bissonnette, PhD
Cross-kingdom EV signalling: what the evidence supports, and what it does not
Plant-derived EVs are taken up by mammalian cells. Their cargo can modulate gene expression in preclinical models. Clinical translation in human skin is where the evidence base is still maturing. Reading the literature requires holding both at once.
Frédéric St-Denis-Bissonnette, PhD
Extracellular vesicles versus PRP for skin applications
PRP and EV preparations are both growth-factor-rich biological inputs that act through cellular signalling. They differ in origin, consistency, delivery, patient experience, and evidence maturity. Treating them as competitors misses the point.
Frédéric St-Denis-Bissonnette, PhD
The biomolecular corona, and why isolation method changes what an EV product actually is
Two preparations from the same biomass can carry different protein coronas if they were isolated by different methods. The corona is part of the active ingredient. Most commercial EV products do not disclose how it was preserved.
Frédéric St-Denis-Bissonnette, PhD
How to evaluate an EV or exosome product before stocking it
Five criteria: source, particle concentration, Certificate of Analysis, isolation method, storage and stability. None are optional. Each one separates a characterized EV preparation from a label that uses the word "exosome" without backing it.
Frédéric St-Denis-Bissonnette, PhD
Aloe barbadensis-derived extracellular vesicles in dermocosmetic formulation
Aloe vera has a 3,000-year cosmetic history. The nanovesicles inside aloe leaf parenchyma are a more recent finding. Their cargo, their stability, and their suitability as a scalable dermocosmetic active deserve separate treatment from the broader plant-EV literature.
Frédéric St-Denis-Bissonnette, PhD
Post-procedure EV protocols: what we can say, and what is still under evaluation
Post-laser, post-microneedling, post-chemical peel: clinics are increasingly asking where EV serums fit. The honest answer requires separating mechanistic plausibility, preclinical signal, and confirmed clinical outcome.
Frédéric St-Denis-Bissonnette, PhD
Working with us on the science.
Clinical evaluators, dermatology partners, and qualified researchers can request the EV SELECT GUIDE or open a direct conversation with the team.